Targeting the Notch Signaling Pathway to Treat Atherosclerosis
Cells · 2026
DOI: 10.3390/cells15161463 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cells, 2026. Verfasst von Alexander Blagov und 5 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Molecular Genetic Modeling of Inflammaging, Institute of General Pathology and Pathophysiology, 8, Baltiiskaya Street, 125315 Moscow, R…. Hauptthemen laut MEDLINE: Atherosclerosis, Receptors, Notch, Signal Transduction, Molecular Targeted Therapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 90 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Russian Science Foundation.
Abstract (Originalsprache)
Atherosclerosis remains the principal underlying cause of myocardial infarction, ischemic stroke and peripheral artery disease, and its progression reflects a complex interplay between lipid accumulation, endothelial dysfunction, chronic vascular inflammation and maladaptive remodeling of the arterial wall. The Notch signaling pathway, an evolutionarily conserved juxtacrine communication system, has emerged as a central regulator of every cell type implicated in atherogenesis, including endothelial cells, vascular smooth muscle cells, monocytes/macrophages and T lymphocytes. Depending on the receptor–ligand pairing, the hemodynamic context and the cellular compartment involved, Notch signaling can be either atheroprotective or atherogenic, a duality that has complicated efforts to translate mechanistic insight into therapy. This review summarizes current knowledge of the molecular architecture of the Notch pathway in the vasculature, dissects its cell type-specific and stage-specific contributions to atherosclerotic plaque initiation, progression, calcification and destabilization, and critically appraises pharmacological strategies designed to modulate Notch activity, including γ-secretase inhibitors, ligand- and receptor-directed monoclonal antibodies, soluble decoy receptors, microRNA-based approaches and drug repurposing strategies such as statins. Particular attention is paid to the cardiovascular toxicities that have emerged from oncology trials of Notch pathway inhibitors, which illustrate both the pharmacological tractability and the narrow therapeutic window of this pathway. We conclude that Notch-directed therapy for atherosclerosis is mechanistically well justified but will require cell type-selective and context-selective delivery strategies to be clinically viable.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Molecular Genetic Modeling of Inflammaging, Institute of General Pathology and Pathophysiology, 8, Baltiiskaya Street, 125315 Moscow, Russia.
- Institute for Atherosclerosis Research, 4-1-207, Osennyaya Street, 121609 Moscow, Russia.
- Department of Commodity Expertise and Customs Business, Plekhanov Russian University of Economics, 36, Stremyanny Lane, 115054 Moscow, Russia.
ORCID-Profile: Daria Borodko, Stanislav Antonov
Förderung
- Russian Science Foundation
Zitieren
APA
Blagov, A., Borodko, D., Rozhkova, U., Antonov, S., Utkina, A., & Kovyanova, T. (2026). Targeting the Notch Signaling Pathway to Treat Atherosclerosis. Cells. https://doi.org/10.3390/cells15161463
Vancouver
Blagov A, Borodko D, Rozhkova U, Antonov S, Utkina A, Kovyanova T. Targeting the Notch Signaling Pathway to Treat Atherosclerosis. Cells. 2026. doi:10.3390/cells15161463
BibTeX
@article{Blagov2026,
author = {Blagov, Alexander and Borodko, Daria and Rozhkova, Ulyana and Antonov, Stanislav and Utkina, Aleksandra and Kovyanova, Tatiana},
title = {Targeting the Notch Signaling Pathway to Treat Atherosclerosis},
journal = {Cells},
year = {2026},
doi = {10.3390/cells15161463}
}
EUVIMED